MDMA for Obsessive-Compulsive Disorder (OCD)

1 paper and 2 clinical trials exploring mdma as a treatment for obsessive-compulsive disorder (ocd).

Compoundempathogen

MDMA

MDMA is a synthetic empathogen that enhances monoamine release, producing prosocial and anxiolytic effects without frank hallucinosis. Two Phase III trials demonstrated significant PTSD symptom reductions, though FDA review raised concerns about blinding, durability, and safety characterisation.

Full MDMA profile
IndicationAbout 1-2% of the population worldwide.

Obsessive-Compulsive Disorder (OCD)

Recent research indicates that psychedelics, particularly psilocybin, are emerging as potential therapeutic agents in the treatment of Obsessive-Compulsive Disorder (OCD). Early clinical trials demonstrate promising results regarding their efficacy and safety, paving the way for future studies in this field.

Full Obsessive-Compulsive Disorder (OCD) profile

Academic Research

1 paper
Open Accessindividual

MDMA-assisted psychotherapy for AUD: Bayesian analysis of WHO drinking risk level and exploratory analysis of drinking behavior and psychosocial functioning at 3 months follow-up

In an open‑label feasibility study of 14 recently detoxified participants, Bayesian analysis estimated a 55–63% probability that MDMA‑assisted psychotherapy produced a two‑level reduction in WHO drinking‑risk at 3‑month follow‑up, with preliminary reductions in alcohol craving and improvements in sleep and psychosocial functioning. The paper frames a harm‑reduction endpoint for AUD and provides early evidence that MDMA‑assisted psychotherapy may improve quality of life alongside reduced drinking.

Published
Journal
Alcohol and Alcoholism
Authors
Durant, C., Higbed, L., Morgan, C. J. A., Nutt, D. J., O'Biren, S., Sessa, B., Szigeti, B., Thurgur, H., Wilson, S.

Clinical Trials

2 trials

Explore further

Search all MDMA papers Search all Obsessive-Compulsive Disorder (OCD) trials Full MDMA profile Full Obsessive-Compulsive Disorder (OCD) profile